213 related articles for article (PubMed ID: 32567217)
1. Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study.
Hu C; Ji B; Hu X; Yang C; Sun W; Zhao X; Li L; Li X; Zhang L
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):291-298. PubMed ID: 32567217
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
3. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.
Ahn LY; Shin KH; Lim KS; Kim TE; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Drug Investig; 2013 Nov; 33(11):817-24. PubMed ID: 24078278
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
5. An assessment of the pharmacokinetics, pharmacodynamics, and tolerability of GCPGC, a novel pegylated granulocyte colony-stimulating factor (G-CSF), in healthy subjects.
Shin KH; Lim KS; Lee H; Jang IJ; Yu KS
Invest New Drugs; 2014 Aug; 32(4):636-43. PubMed ID: 24468886
[TBL] [Abstract][Full Text] [Related]
6. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats.
Kang JS; Lee KC
Biol Pharm Bull; 2013; 36(7):1146-51. PubMed ID: 23811564
[TBL] [Abstract][Full Text] [Related]
7. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics and pharmacodynamics of pegylated recombinant human granulocyte colony-stimulating factor in children with acute lymphoblastic leukemia: a prospective control trial].
Yang WY; Liu TF; Chen XJ; Guo Y; Li T; Qi BQ; Liu F; Chang LX; Ruan M; Liu XM; Zhang L; Zou Y; Chen YM; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Nov; 22(11):1172-1177. PubMed ID: 33172550
[TBL] [Abstract][Full Text] [Related]
10. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats.
Tanaka H; Satake-Ishikawa R; Ishikawa M; Matsuki S; Asano K
Cancer Res; 1991 Jul; 51(14):3710-4. PubMed ID: 1712246
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of pegylated recombinant human granulocyte colony-stimulating factor in children with acute leukaemia.
Liu XT; Zhao YX; Jia GW; Yang F; Zhang CZ; Han B; Dai JH; Han YQ; Tang BH; Yang XM; Shi HY; Zhou Y; Sui ZG; Chen JZ; van den Anker JN; Zhao W
Br J Clin Pharmacol; 2021 Aug; 87(8):3292-3300. PubMed ID: 33506975
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing.
Sturgill MG; Huhn RD; Drachtman RA; Ettinger AG; Ettinger LJ
Am J Hematol; 1997 Feb; 54(2):124-30. PubMed ID: 9034286
[TBL] [Abstract][Full Text] [Related]
15. Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.
Buchner A; Lammerich A; Abdolzade-Bavil A; Müller U; Bias P
Curr Med Res Opin; 2014 Dec; 30(12):2523-33. PubMed ID: 25251999
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB; Kido A
Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of the salvage therapy using pegylated recombinant human granulocyte colony stimulating factor for grade IV neutropenia induced by concurrent chemoradiotherapy].
Wu F; Wang H; Li N; Guo Y; Cheng Y; Liu Q; Yang X; Wan X; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):708-12. PubMed ID: 25564064
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic analysis of neutrophil proliferation induced by recombinant granulocyte colony-stimulating factor (rhG-CSF): comparison between intravenous and subcutaneous administration.
Sugiura M; Yamamoto K; Sawada Y; Iga T
Biol Pharm Bull; 1997 Jun; 20(6):684-9. PubMed ID: 9212991
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.
Scholz M; Engel C; Apt D; Sankar SL; Goldstein E; Loeffler M
Cell Prolif; 2009 Dec; 42(6):823-37. PubMed ID: 19780759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]